Immutep Ltd (AU:IMM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Limited announced that all resolutions proposed at their 2024 Annual General Meeting were successfully passed, showcasing strong shareholder support. The company, a leader in LAG-3 immunotherapy for cancer and autoimmune diseases, continues to focus on advancing its innovative treatment options. This positive outcome is likely to strengthen investor confidence and potentially impact stock performance favorably.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.